JP2015531873A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015531873A5 JP2015531873A5 JP2015531492A JP2015531492A JP2015531873A5 JP 2015531873 A5 JP2015531873 A5 JP 2015531873A5 JP 2015531492 A JP2015531492 A JP 2015531492A JP 2015531492 A JP2015531492 A JP 2015531492A JP 2015531873 A5 JP2015531873 A5 JP 2015531873A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- subject
- sample
- fgf
- specifically binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 38
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 claims 22
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 15
- 238000001514 detection method Methods 0.000 claims 15
- 238000003384 imaging method Methods 0.000 claims 13
- 230000000747 cardiac effect Effects 0.000 claims 11
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 claims 7
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 claims 7
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 7
- 206010019280 Heart failures Diseases 0.000 claims 5
- 229930003316 Vitamin D Natural products 0.000 claims 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 5
- 230000007211 cardiovascular event Effects 0.000 claims 5
- 235000019166 vitamin D Nutrition 0.000 claims 5
- 239000011710 vitamin D Substances 0.000 claims 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 5
- 229940046008 vitamin d Drugs 0.000 claims 5
- 102400001047 Endostatin Human genes 0.000 claims 4
- 108010079505 Endostatins Proteins 0.000 claims 4
- 238000007435 diagnostic evaluation Methods 0.000 claims 4
- 230000002861 ventricular Effects 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000000717 retained effect Effects 0.000 claims 2
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 102100026632 Mimecan Human genes 0.000 claims 1
- 108091013859 Mimecan Proteins 0.000 claims 1
- 102400001263 NT-proBNP Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000004364 calculation method Methods 0.000 claims 1
- 238000002592 echocardiography Methods 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12184085.4 | 2012-09-12 | ||
| EP12184085 | 2012-09-12 | ||
| PCT/EP2013/056706 WO2014040759A1 (en) | 2012-09-12 | 2013-03-28 | Identification of patients with abnormal fractional shortening |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017220660A Division JP6615848B2 (ja) | 2012-09-12 | 2017-11-16 | 異常な短縮率（ｆｒａｃｔｉｏｎａｌ ｓｈｏｒｔｅｎｉｎｇ）を持つ患者の同定 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531873A JP2015531873A (ja) | 2015-11-05 |
| JP2015531873A5 true JP2015531873A5 (enExample) | 2016-05-19 |
| JP6247302B2 JP6247302B2 (ja) | 2017-12-13 |
Family
ID=46826365
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531492A Active JP6247302B2 (ja) | 2012-09-12 | 2013-03-28 | 異常な短縮率（ｆｒａｃｔｉｏｎａｌｓｈｏｒｔｅｎｉｎｇ）を持つ患者の同定 |
| JP2017220660A Active JP6615848B2 (ja) | 2012-09-12 | 2017-11-16 | 異常な短縮率（ｆｒａｃｔｉｏｎａｌ ｓｈｏｒｔｅｎｉｎｇ）を持つ患者の同定 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017220660A Active JP6615848B2 (ja) | 2012-09-12 | 2017-11-16 | 異常な短縮率（ｆｒａｃｔｉｏｎａｌ ｓｈｏｒｔｅｎｉｎｇ）を持つ患者の同定 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20150185230A1 (enExample) |
| EP (3) | EP4075143A1 (enExample) |
| JP (2) | JP6247302B2 (enExample) |
| CN (1) | CN104620111B (enExample) |
| CA (1) | CA2883890C (enExample) |
| ES (2) | ES2913539T3 (enExample) |
| WO (1) | WO2014040759A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3088900B1 (en) | 2011-10-17 | 2020-08-12 | Roche Diagniostics GmbH | Troponin as marker for intermittent atrial fibrillation |
| ES2939018T3 (es) | 2014-03-26 | 2023-04-18 | Hoffmann La Roche | IGFBP7 para diagnosticar una disfunción diastólica |
| CN110514846A (zh) | 2014-10-29 | 2019-11-29 | 豪夫迈·罗氏有限公司 | 用于死亡的风险预测的生物标志物 |
| CN108139409B (zh) | 2015-10-08 | 2020-07-24 | 豪夫迈·罗氏有限公司 | 当在外科手术之前测量时用于预测aki的风险的igfbp7 |
| WO2017125406A1 (en) * | 2016-01-19 | 2017-07-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting left ventricular remodeling in subjects suffering from hypertension |
| WO2018222783A1 (en) * | 2017-05-30 | 2018-12-06 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers |
| JP7058331B2 (ja) | 2017-12-13 | 2022-04-21 | エフ．ホフマン－ラ ロシュ アーゲー | 脳卒中の予測のための循環アンジオポエチン－２（Ａｎｇ－２）およびインスリン様増殖因子結合タンパク質７（ＩＧＦＢＰ７） |
| JP7024576B2 (ja) * | 2018-04-20 | 2022-02-24 | オムロンヘルスケア株式会社 | 電子血圧計および心不全検出器 |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| CN118922721A (zh) * | 2022-03-18 | 2024-11-08 | 豪夫迈·罗氏有限公司 | 用于2型与1型急性心肌梗死的早期辨别的cMyBPC标志物组合 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| US6709855B1 (en) | 1998-12-18 | 2004-03-23 | Scios, Inc. | Methods for detection and use of differentially expressed genes in disease states |
| EP1379869A4 (en) * | 2001-03-15 | 2004-08-11 | Xiao Yong Fu | METHOD FOR THERAPEUTICALLY TREATING A CLINICALLY DETECTED CARDIOPATHOLOGICAL FORM IN A MAMMAL |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| US7632647B2 (en) | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| DE60233301D1 (de) | 2001-05-04 | 2009-09-24 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
| CA2467456A1 (en) * | 2001-11-19 | 2003-05-30 | Protometrix, Inc. | Method of using a non-antibody protein to detect and measure an analyte |
| JP2005291899A (ja) * | 2004-03-31 | 2005-10-20 | Akira Matsumori | 心疾患の検査法 |
| US8563328B2 (en) * | 2004-07-26 | 2013-10-22 | University Of Louisville Research Foundation, Inc. | Fiber-optic biosensor and biosensing methods |
| US20080027330A1 (en) * | 2006-05-15 | 2008-01-31 | Endothelix, Inc. | Risk assessment method for acute cardiovascular events |
| WO2008060618A2 (en) * | 2006-11-15 | 2008-05-22 | University Of Florida Research Foundation | Use of genetic determinants in cardiovascular risk assessment |
| EP2115477B1 (en) * | 2007-01-25 | 2015-06-24 | Roche Diagnostics GmbH | Use of igfbp-7 in the assessment of heart failure |
| US8182998B2 (en) * | 2007-04-26 | 2012-05-22 | Genera Istrazivanja D.O.O. | Blood biomarkers for bone fracture and cartilage injury |
| EP2153232A1 (en) * | 2007-05-18 | 2010-02-17 | Duke University | Serum biomarkers for the early detection of lung cancer |
| WO2009091556A2 (en) * | 2008-01-17 | 2009-07-23 | The General Hospital Corporation | Diagnostic methods and kits using fibroblast growth factor-23 |
| NZ593221A (en) * | 2008-11-06 | 2012-10-26 | Musc Found For Res Dev | Detecting and monitoring left ventricular hypertrophy and congestive heart failure by profiling biomarkers |
| EP2414320A1 (en) | 2009-04-01 | 2012-02-08 | LEK Pharmaceuticals d.d. | A process for dimethylation of active methylene groups |
| CN102422157B (zh) * | 2009-04-27 | 2014-10-29 | 霍夫曼-拉罗奇有限公司 | 内皮抑制素作为心力衰竭标记的应用 |
| WO2011012268A1 (en) | 2009-07-27 | 2011-02-03 | Roche Diagnostics Gmbh | Use of mimecan in the assessment of heart failure |
| ES2818138T3 (es) * | 2009-12-20 | 2021-04-09 | Astute Medical Inc | Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| EP2553461B1 (en) * | 2010-03-26 | 2016-01-20 | Mycartis N.V. | Ltbp2 as a biomarker for renal dysfunction and glomerular filtration rate |
| US20120142632A1 (en) * | 2010-08-04 | 2012-06-07 | St. Vincent's Institute Of Medical Research | Diagnostic and prognostic assay |
| EP2796874B1 (en) * | 2010-08-26 | 2017-03-08 | Roche Diagnostics GmbH | Use of biomarkers in monitoring a medication in a subject suffering from heart failure |
| EP3578979B1 (en) * | 2010-08-31 | 2022-02-23 | Minaris Medical Co., Ltd. | Method for measuring fibroblast growth factor-23 and reagent therefor |
-
2013
- 2013-03-28 EP EP22161423.3A patent/EP4075143A1/en active Pending
- 2013-03-28 JP JP2015531492A patent/JP6247302B2/ja active Active
- 2013-03-28 ES ES18174585T patent/ES2913539T3/es active Active
- 2013-03-28 CA CA2883890A patent/CA2883890C/en active Active
- 2013-03-28 EP EP18174585.2A patent/EP3428649B1/en active Active
- 2013-03-28 CN CN201380047272.0A patent/CN104620111B/zh active Active
- 2013-03-28 WO PCT/EP2013/056706 patent/WO2014040759A1/en not_active Ceased
- 2013-03-28 ES ES13713175.1T patent/ES2680149T3/es active Active
- 2013-03-28 EP EP13713175.1A patent/EP2895866B1/en active Active
-
2015
- 2015-03-11 US US14/644,695 patent/US20150185230A1/en not_active Abandoned
-
2017
- 2017-11-16 JP JP2017220660A patent/JP6615848B2/ja active Active
-
2018
- 2018-03-05 US US15/911,699 patent/US11454634B2/en active Active
-
2022
- 2022-08-19 US US17/891,458 patent/US20220412991A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015531873A5 (enExample) | ||
| Winau et al. | High-sensitive troponin is associated with subclinical imaging biosignature of inflammatory cardiovascular involvement in systemic lupus erythematosus | |
| Imran et al. | Native T1 mapping in the diagnosis of cardiac allograft rejection: a prospective histologically validated study | |
| Carrick et al. | Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors | |
| Klok et al. | External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism | |
| Andruchow et al. | Contemporary emergency department management of patients with chest pain: a concise review and guide for the high-sensitivity troponin era | |
| Rusconi et al. | Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure | |
| Jing et al. | Ambulatory systolic blood pressure and obesity are independently associated with left ventricular hypertrophic remodeling in children | |
| Ray et al. | Pulmonary arterial stiffness assessed by cardiovascular magnetic resonance imaging is a predictor of mild pulmonary arterial hypertension | |
| Mayr et al. | Evaluation of myocardial involvement in patients with connective tissue disorders: a multi-parametric cardiovascular magnetic resonance study | |
| McComb et al. | Assessment of the relationships between myocardial contractility and infarct tissue revealed by serial magnetic resonance imaging in patients with acute myocardial infarction | |
| JP2015504519A5 (enExample) | ||
| Kobayashi et al. | Urinary 8-hydroxy-2′-deoxyguanosine as a novel biomarker of inflammatory activity in patients with cardiac sarcoidosis | |
| CN109891243A (zh) | 心房纤颤和中风的评价中的循环esm-1 (endocan) | |
| Ross et al. | Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review | |
| JP5847221B2 (ja) | アルツハイマー病罹患リスクを検出する方法 | |
| Deraz et al. | Assessment of ventricular dysfunction in Egyptian children with Beta-thalassemia major | |
| Schaaf et al. | Which high-sensitivity troponin variable best characterizes infarct size and microvascular obstruction? | |
| Yamasaki et al. | Clinical impact of left ventricular eccentricity index using cardiac MRI in assessment of right ventricular hemodynamics and myocardial fibrosis in congenital heart disease | |
| Abe et al. | Right ventricular dimension index by cardiac magnetic resonance for prognostication in connective tissue diseases and pulmonary hypertension | |
| Fairley et al. | Prognostic and functional importance of both overt and subclinical left ventricular systolic dysfunction in systemic sclerosis | |
| Casals et al. | Impact of ultrasensitive cardiac troponin I dynamic changes in the new universal definition of myocardial infarction | |
| Liu et al. | A prospective study examining the role of myocardial F ibrosis in outcome following mitral valve repair IN DE generative mitral R egurgitation: rationale and design of the mitral FINDER study | |
| Fouad-Tarazi et al. | Blood volume measurement as a tool in diagnosing syncope | |
| Broekhuizen et al. | Accuracy of symptoms, signs, and C-reactive protein for early chronic obstructive pulmonary disease |